A high-beta, short-duration psychedelic “infrastructure play” built to fit the 2-hour Spravato clinic model—powered by BPL-003, but hostage to Phase 3 and Schedule I rescheduling.
Overview
AtaiBeckley Inc. (formerly ATAI Life Sciences N.V.) is a clinical-stage biopharmaceutical company focused on transforming psychiatric care through psychedelic-based and novel mental health therapeutics. It operates a decentralized, vertically integrated “hub-and-spoke” structure intended to diversify clinical risk while concentrating neuro-pharmacology expertise across majority/wholly owned entities. In 2025, the company underwent a major strategic transformation: it merged with Beckley Psytech Limited and redomiciled from the Netherlands to the U.S. (Delaware), improving institutional positioning and simplifying the path toward late-stage clinical execution. The company targets high unmet-need interventional psychiatry indications including Treatment-Resistant Depression (TRD), Social Anxiety Disorder (SAD), and Opioid Use Disorder (OUD), with a value proposition centered on **short-duration psychedelic experiences** that can be administered within a standard two-hour clinic workflow (comparable to J&J’s Spravato model). As a pre-commercial entity, it generates only limited “non-core” revenue from collaboration agreements, service/management fees to investees, and grants (e.g., NIDA). Q3 2025 revenue was ~$0.74M (vs. $0.04M prior year), with $3.02M for the first nine months of 2025. The investment case hinges on the clinical success and regulatory pathway of its lead assets—particularly BPL-003—rather than current revenue. Following an October 2025 public offering, AtaiBeckley reports ~**$264M in pro-forma cash and liquid assets**, providing runway into **2029** to fund key trials, including the pivotal Phase 3 program for BPL-003.